Global Nateglinide Market: Introduction

Nateglinide is an oral antihyperglycemic agent. It belongs to the meglitinide class of short-acting insulin secretagogues. It is used for the treatment of non-insulin-dependent diabetes mellitus. The agent acts by binding to β cells of the pancreas to stimulate and regulate insulin release. Nateglinide is an amino acid derivative. It induces an early insulin response to meals decreasing postprandial blood glucose levels. Meglitinides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Meglitinides may cause hypoglycemia due to their mechanism of action. However, the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. Nateglinide is used alone or with other medications to control high blood sugar along with a proper diet and exercise program.

Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). Major metabolites possess less activity than the parent compound.

Are you a Start-up willing to make it big in the Business? Grab an Exclusive PDF Brochure of Nateglinide Market Report

Key Drivers of Global Nateglinide Market

Rapid Growth in Prevalence of Diabetes

According to the World Health Organization (WHO), the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. The global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. Diabetes prevalence has been rising more rapidly in middle- and low-income countries. Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke, and lower limb amputation. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Another 2.2 million deaths were attributable to high blood glucose in 2012. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. The WHO estimated that diabetes was the seventh leading cause of death in 2016.

Increase in Prevalence of Obesity

According to the WHO, global prevalence of obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these, over 650 million were obese. 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese. Most of the world's population lives in countries where overweight and obesity kills more people than underweight. 40 million children under the age of 5 were overweight or obese in 2018. Over 340 million children and adolescents aged 5 to 19 were overweight or obese in 2016.

North America to Account for Major Share of Global Nateglinide Market

  • North America is projected to account for major share of the global nateglinide market during the forecast period. The market in the region is anticipated to grow at a rapid pace in the next few years due to increase in prevalence of diabetes disorders and new digital technologies and the availability of developed health care infrastructure. Europe is expected to be the second largest market during the forecast period.
  • The nateglinide market in Asia Pacific is likely to expand at a high CAGR during the forecast period. This can be attributed to increase in geriatric population is high in the region.

Expanding Operations in Future? To Get the Perfect Launch Ask for a Custom Nateglinide Market Report

Key Players Operating in Global Nateglinide Market

The global nateglinide market is highly consolidated, with the presence of a small number of key players. Leading players operating in the global nateglinide market are:

  • Novartis Europharm Limited
  • Caremark L.L.C.
  • AvKARE, Inc.
  • Avera McKennan Hospital
  • Zydus Pharmaceuticals (USA) Inc.
  • Nivagen Pharmaceuticals, Inc.
  • American Health Packaging
  • Par Pharmaceutical, Inc.
  • Wilshire Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Limited
  • Cadila Healthcare Limited
  • Actavis Pharma, Inc.  

Global Nateglinide Market: Research Scope

Global Nateglinide Market, by Device Therapy

  • Monotherapy
  • Combinational Therapy

Global Nateglinide Market, by Indication

  • Decreased Blood Glucose      
  • Diabetes
  • Hyperglycemia                       
  • Type 2 Diabetes Mellitus       
  • Decreased Weight

Global Nateglinide Market, by Distribution Channel

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Global Nateglinide Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Disclaimer: This ongoing market research study is a meticulously planned activity where a broad array of factors and aspects that shape the marketing environment and industry are taken into account. However, keeping in mind the constantly changing nature of business dynamics and changing strategic intents, we are always actively making iterations and modifications in our approaches. As always, we are ready to tailor our insights and guidance to suit your requirements. Engage with us to know what more is there for your CXOs.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying